Orbimed Advisors LLC lessened its stake in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) by 46.3% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 804,996 shares of the company's stock after selling 695,004 shares during the period. Orbimed Advisors LLC owned about 0.50% of Neumora Therapeutics worth $8,533,000 at the end of the most recent reporting period.
Other large investors have also modified their holdings of the company. Swiss National Bank purchased a new stake in shares of Neumora Therapeutics during the fourth quarter valued at $1,168,000. Schonfeld Strategic Advisors LLC lifted its stake in Neumora Therapeutics by 273.9% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 521,013 shares of the company's stock valued at $5,523,000 after buying an additional 381,676 shares in the last quarter. Capital International Investors lifted its stake in Neumora Therapeutics by 692.1% during the fourth quarter. Capital International Investors now owns 3,700,359 shares of the company's stock valued at $39,224,000 after buying an additional 3,233,179 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Neumora Therapeutics by 23.0% in the fourth quarter. Wells Fargo & Company MN now owns 70,653 shares of the company's stock worth $749,000 after buying an additional 13,196 shares during the period. Finally, KLP Kapitalforvaltning AS purchased a new position in shares of Neumora Therapeutics in the fourth quarter worth approximately $143,000. 47.65% of the stock is owned by institutional investors.
Neumora Therapeutics Price Performance
Shares of Neumora Therapeutics stock opened at $0.69 on Tuesday. The firm has a market cap of $112.01 million, a price-to-earnings ratio of -0.37 and a beta of 2.96. The stock has a 50-day simple moving average of $0.91 and a 200-day simple moving average of $4.56. Neumora Therapeutics, Inc. has a 52-week low of $0.62 and a 52-week high of $17.19.
Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.02). As a group, equities research analysts predict that Neumora Therapeutics, Inc. will post -1.61 earnings per share for the current year.
Analyst Ratings Changes
A number of equities analysts recently commented on NMRA shares. Guggenheim lowered shares of Neumora Therapeutics from a "buy" rating to a "neutral" rating in a research note on Friday, March 7th. Royal Bank of Canada restated a "sector perform" rating and issued a $4.00 target price on shares of Neumora Therapeutics in a report on Tuesday, March 4th. Needham & Company LLC reiterated a "buy" rating and set a $5.00 price target on shares of Neumora Therapeutics in a report on Thursday, April 10th. Stifel Nicolaus lowered Neumora Therapeutics from a "buy" rating to a "hold" rating and dropped their price target for the company from $6.00 to $2.00 in a research report on Friday, March 7th. Finally, William Blair lowered Neumora Therapeutics from an "outperform" rating to a "market perform" rating in a research report on Monday, March 10th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating to the company. According to MarketBeat, the company has an average rating of "Hold" and an average target price of $9.29.
View Our Latest Stock Report on NMRA
About Neumora Therapeutics
(
Free Report)
Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Neumora Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neumora Therapeutics wasn't on the list.
While Neumora Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
